Feature
BiotechTV: Professor Carlo Rinaldi on Advancing Therapies for SBMA and Friedreich’s Ataxia
February 20, 2026
In a recent BiotechTV interview, Professor Carlo Rinaldi, MD, PhD, Neurological Disorders Theme Lead and 2024 Oxford-Harrington Rare Disease Scholar, discusses how support from the Oxford-Harrington Rare Disease Centre (OHC) is advancing new therapies for Spinal-bulbar muscular atrophy (SBMA) and Friedreich’s Ataxia (FA).
In addition to his 2024 Oxford-Harrington Rare Disease Scholar Award, Professor Rinaldi has been awarded funding through the FA Alliance Innovation Fund, coordinated by OHC, to develop innovative therapeutic approaches targeting the underlying biology of FA. In the interview, he reflects on how OHC’s combination of funding and translational expertise is helping accelerate progress toward clinical application.